David Roman

could you go into further detail on your guidance philosophy and your thought process in establishing the revised outlook

can you help us sort of frame the Abbott Laboratories portfolio in EP maybe looking back six months, where we are today

could you maybe talk a little bit more on some of the underlying drivers of the business and how you think about an overall acceleration in the Diagnostics business going forward

help us think through the headwinds you're seeing this year, the extent to which those are transient versus more permanent changes

think about where you're positioned and how you accelerate this business back toward end market growth

you could go into a little bit more detail on the Structural Heart business

can you unpack for us a little bit what's going on beyond some of those businesses, for example, with the IV set business? How do you protect the pump disposal business, given the Novum dynamics?

what are the signposts that you're seeing whether it's KPIs or orders or other customer dynamics that give you that confidence to embed such a significant ramp in the back half of the year?

Can you just remind us on where you are and the progress you are making on reducing the G&A and support costs that today are getting reimbursed by Vantiv via the TSA?

What are you doing to ensure sustainability of the business as it relates to the competitive dynamic? And how are you gaining sufficient visibility to drive the forecasting process?

as you think about the forward identity for Baxter, is this a med-tech company in your eyes? Is this a diversified manufacturing company? And what decisions are you going to make that ultimately al...

you are seeing a lot of the growth come from, I think, lower-margin segments like compounding versus anesthesia and injectables. Can you maybe help us think about the implications from the drivers ...

can you maybe help us think about the time lines of working down stranded costs and the process by which the TSAs roll off? And how do you avoid a gap there, whereby the TSA roll-off is faster than...

can you give us any parameters to frame how to think about that? Because if a pharma tariff is announced between now and when you report earnings again, we're all going to try to quantify it

as you remove hospitals from allocation, can you maybe help us frame what you expect the impact to be to your business? And then also if you think hospitals will return to pre-hurricane inventory m...

Joel, can you walk us through the post Vantive sale capital structure of the company and maybe update us on target leverage ratios and the timeframe to achieve that?

Can you help us think about the direction of the company from here and how you're thinking about strategic priorities and maybe at the same time give us a flavor for how that fits into the profilin...

what are the opportunities on the pump disposable side, especially given the disruption in a competitor

I wanted to just to dig in a little bit more here on the P&L. And as we look at FY '25, there are some sort of discrete items here

maybe you could unpack a little bit for us in more detail kind of where you see that cohort of the business going

what investments and processes are you putting in place to make sure that you're seeing consistency and performance

outside EP and WATCHMAN, there's obviously a disproportionate focus on those businesses given how strong a growth contribution they've been

Are you at a point now given the top line it's becoming more challenging to spend all the upside

where you are in kind of capturing the totality of the EP market from a procedure and indication perspective

what are the drivers to move that back towards a high single-digit growth rate, especially as Silk turns organic

can you maybe help us think about the segment of the market that you're not able to address today

as you think about retaining the earnings guidance with the top line reduction

to what extent you're contemplating reinvesting that and whether that is showing up in the P&L now?

can you give us just a little bit more detail on the nature of some of the reorganization efforts that you've undertaken here?

what is assumed from sort of underlying volume growth at different ends of the guidance range

Can you maybe go into a little bit more detail about some of the actions you're going to undertake to ensure that, that message is clear within the broader community

what does that mean to overall utilization rates? And what are some of the opportunities you have to drive higher retention in that population

Are you seeing a class effect on TAVR? Is this questioning device selection for lifetime management?

Also any early perspective on how M3 might be impacting the business?

go into a little bit more detail on the comments regarding lifetime management for TAVR and maybe more specifically talk about what you think the implications will be to valve and vendor selection

is it reasonable to expect that just a significant percentage of patients receiving TAVR either in the asymptomatic or call it the sub-seventy-five population, that creates a unique opportunity for...

When you look at the PREVUE-VALVE study that was presented at TCT and think about the early TAVR study in context, can you maybe just help us look forward

Can you maybe help us think through how to compare and contrast the M3 launch with EVOQUE

the company was generating 10% plus top line growth with low 30s operating margins. Is it realistic to think that, that is the direction you aim to take the business

talk us through a little bit what you're seeing on the ground as it relates to either referral patterns or physician engagement post the presentation

How should we think about mix between repair and replacement today and going forward

help us piece together the sequential deceleration and then correspondingly, the acceleration reflected in the full year outlook

help us reflect a little bit on some of the dynamics that drove the performance here in 2024 that ended above your expectations

Could you just elaborate a little bit further on the commercial strategy here?

Could you maybe help us understand a little bit more detail just on the phasing and impact

do you freeze the market in anticipation of some of these new product launches

We did see an acceleration in that franchise in 2020 in the fourth quarter, excuse me

how long this transition between R&D and COGS takes place

what are you seeing specifically on the opportunity in the ASC setting for EP

how we should contextualize the back half revenue guidance against that algorithm

how the expectations around Flyrcado may be impacting your ability to see benefits across the entirety of the PET/CT

the magnitude of mitigation actions that are already in place versus those that need to be implemented

how are you thinking about M&A? Isn't this a prime environment to kind of accelerate those efforts

help us understand sort of the inflection point that you saw in that business this quarter with respect to growth

how are you prioritizing markets outside the U.S.? And what is, broadly speaking, the strategy here

give us a sense of kind of where we are in bringing SP to a point where that adoption curve can accelerate

how you saw these dynamics play out through the back half of 2025

is there anything left either from a technology standpoint, maybe a vessel sealer that you think would be necessary to really unlock the opportunity?

You've had a number of SP clearances over the past six months or so. Maybe just help us contextualize performance

how you're seeing that unfold and where force feedback fits into that trajectory

Can you maybe give us an update on your latest thinking on the capital side and how you're approaching those conversations

it looks like I&A outgrew procedure volumes this quarter, whether that's having a positive impact even in its early launch

maybe, Gary, you could expand a little bit on the comment made earlier about Intuitive being potentially part of the solution and not part of the problem

Is this something that you're observing today as you talk to customers outside the US or even in the US? Or are you just calling out a theoretical impact

can you help us think through which parts of sort of the surgical ecosystem you've captured today? And maybe give us some sense of where that might be going

I wanted to come back to just the overall MedTech strategy. And I appreciate that you exited the year over the 7% number

there do seem to be a lot of other unresolved considerations on tariffs, such as USMCA and then 232.

Maybe you could help frame the past year, some of your observations here. What's gone in line with your expectations? What's gone better? Where are the areas where you're focused

the outlook implies kind of high teens growth in the back half of the year. Can you help us unpack that a little further on a geographic basis and your confidence in the 20% LRT guidance

Can you talk a little bit more about how the adoption is built over the past year, where we are in kind of an uptake

Can you maybe go into a little bit more detail there on how demand has shaped up relative to expectations? And if that acceleration in CapEx is a reflection of a view of demand tracking ahead of or...

you would expect 2026 growth to improve versus 2025 and continue to put you on a trajectory toward the LRP targets

How did you think about deploying the buyback in the quarter? Were there competing considerations for capital

Can you give us more flavor on the volume versus mix contribution, and what you are seeing from a new product launch perspective year to date

what's sort of the strategy behind the buyback? And what are the factors that would drive you to deploy it either on a programmatic or more significant basis

maybe you could just extrapolate the experience in Dental to when we could -- when you think it's reasonable to expect that same dynamic to play through in MedSurg and HIS

as you look at -- on an underlying basis, it sounds like both Infection Prevention and Advanced Wound Care are tracking ahead of where your original expectations are

maybe you could just sort of unpack for us what are the factors influencing the topline performance as you exit 2024

It looks like a lot of the commercial and sales force challenges had already faded behind you exiting 2025. Maybe you could give us an update

it does look like you've reaccelerated your relative performance versus peers, especially in Orthopaedics and markets outside the U.S.

as he takes on perhaps more some of the day-to-day operational responsibilities, Kevin, are there priorities where you can now allocate more time

Maybe any latest thinking on just your robotics strategy from a portfolio standpoint as you roll out Mako four and any updates you can provide on the handheld instrumentation

coming into the year, you had contemplated not realizing the same level of benefits that you accrued in 2024. Can you just talk to us about what has evolved

It sounds like you're getting very close fully hitting an inflection on that rollout. How should we think about kind of maybe what's transpired here

how we should think about the addressable market here, the pace of adoption, if knees or hips was a good proxy and how the robotic shoulder market should kind of evolve

the acquisitions you had completed in 2024 were expected to contribute about $300 million this year. Can you maybe just give us an update

it does look like orthopedic markets have slowed a little bit. Your commentary around July is obviously encouraging for Zimmer, but maybe you could contextualize results here and what you're seeing...

can you maybe firstly update us on how the trajectory of gross margins are trending relative to those expectations